{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Torrance",
      "state": "CA",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "77161",
      "recalling_firm": "Sato Pharmaceutical Inc.",
      "address_1": "20695 S Western Ave Ste 240",
      "address_2": "",
      "postal_code": "90501-1834",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "US: Hawaii, Guam, Saipan, SPI",
      "recall_number": "D-0855-2017",
      "product_description": "SATO CLEAR (naphazoline hydrochloride) Redness Reliever Eye Drops, packaged in 0.5 FL OZ (15mL) bottles, Manufactured by SATO Pharmaceuticals CO., LTD. 1-5-27 Motoakasaka Minato-Ku Tokyo, Japan, NDC 49873-044-01",
      "product_quantity": "4,790 bottles",
      "reason_for_recall": "Lack of Assurance of Sterility: Firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.",
      "recall_initiation_date": "20170216",
      "center_classification_date": "20170523",
      "termination_date": "20180313",
      "report_date": "20170531",
      "code_info": "Lot #: WXWZ, Exp. March 2019;  WXTS, Exp. October 2019",
      "more_code_info": ""
    }
  ]
}